Lantheus
LNTH
Collegium Pharmaceutical
COLL
Constellation Brands
STZ
Halozyme Therapeutics
HALO
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -71.01%13.2M | -38.38%14.99M | 40.97%-5.85M | -52.47%12.89M | -322.88%-8.84M | 172.97%45.51M | 188.16%24.32M | -165.54%-9.91M | 6,409.30%27.13M | 161.39%3.97M |
Net income from continuing operations | -27.53%-41.08M | 14.19%-8.84M | 23.52%-10.14M | -453.45%-14.04M | -31.85%-8.06M | -323.81%-32.21M | -229.07%-10.31M | -192.83%-13.26M | -159.41%-2.54M | 11.45%-6.11M |
Operating gains losses | -12.33%256K | -132.76%-229K | 2,204.76%484K | 127.55%27K | 92.12%-26K | 111.79%292K | 263.32%699K | 101.31%21K | -136.70%-98K | 53.78%-330K |
Depreciation and amortization | -5.92%50.03M | -8.66%12.14M | -8.58%12.34M | -5.57%12.74M | -0.68%12.82M | 8.72%53.18M | 6.52%13.29M | 15.05%13.5M | 9.52%13.49M | 4.14%12.91M |
Other non cash items | -1.83%7.71M | 9.70%1.92M | 7.41%2.32M | -4.33%1.74M | -18.67%1.72M | 96.30%7.85M | -4.88%1.75M | 217.35%2.16M | 120.17%1.82M | 226.54%2.12M |
Change In working capital | -177.12%-8.93M | -52.88%8.46M | 13.91%-12.23M | -18.54%10.94M | -187.16%-16.1M | 121.68%11.58M | 225.28%17.96M | -27.90%-14.2M | 194.31%13.43M | 59.15%-5.61M |
-Change in receivables | -59.22%6.72M | 54.45%-1.53M | -52.96%4.56M | 74.67%6.23M | -138.44%-2.53M | 140.11%16.49M | -145.93%-3.35M | 161.72%9.69M | 141.87%3.57M | 142.40%6.59M |
-Change in inventory | -67.24%1.71M | 4.19%4.11M | 2.74%3.49M | -210.56%-3.65M | 58.88%-2.23M | 122.72%5.22M | 141.81%3.94M | 171.71%3.39M | 183.21%3.31M | -12.05%-5.42M |
-Change in prepaid assets | -186.67%-995K | -25.48%-4.58M | 0.64%1.74M | 23.12%2.28M | -135.19%-430K | 240.34%1.15M | -54.99%-3.65M | 35.08%1.73M | -33.61%1.85M | 148.34%1.22M |
-Change in payables and accrued expense | -297.73%-2.09M | -42.46%13.87M | 28.22%-18.65M | 12.80%10.49M | -22.64%-7.8M | -94.57%1.06M | 3,602.30%24.1M | -367.64%-25.99M | 606.70%9.3M | -158.05%-6.36M |
-Change in other current liabilities | -5.96%-13.08M | 4.19%-3.27M | 0.03%-3.27M | -5.93%-3.29M | -27.24%-3.25M | -41.92%-12.34M | ---3.41M | ---3.28M | ---3.1M | ---2.56M |
-Change in other working capital | -17,171.43%-1.2M | -142.81%-140K | -131.35%-79K | 25.08%-1.11M | -84.92%138K | -99.03%7K | -95.23%327K | 115.17%252K | 45.03%-1.49M | 151.72%915K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -71.01%13.2M | -38.38%14.99M | 40.97%-5.85M | -52.47%12.89M | -322.88%-8.84M | 172.97%45.51M | 188.16%24.32M | -165.54%-9.91M | 6,409.30%27.13M | 161.39%3.97M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 38.77%-14.18M | 64.44%-3M | 14.72%-3.08M | 54.73%-2.63M | -3.33%-5.46M | 8.89%-23.16M | 55.96%-8.44M | 21.75%-3.62M | -96.02%-5.82M | -494.33%-5.28M |
Net PPE purchase and sale | 38.77%-14.18M | 64.44%-3M | 14.72%-3.08M | 54.73%-2.63M | -3.33%-5.46M | 8.89%-23.16M | 55.96%-8.44M | 21.75%-3.62M | -96.02%-5.82M | -494.33%-5.28M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 38.77%-14.18M | 64.44%-3M | 14.72%-3.08M | 54.73%-2.63M | -3.33%-5.46M | 8.89%-23.16M | 55.96%-8.44M | 21.75%-3.62M | -96.02%-5.82M | -494.33%-5.28M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 81.08%-1.68M | -83.98%433K | 90.96%-1.4M | 471.89%5.5M | -216.45%-6.22M | -283.40%-8.89M | -59.38%2.7M | -36.49%-15.46M | -124.86%-1.48M | 49.82%5.34M |
Net issuance payments of debt | 96.69%-9.33M | -79.89%571K | 82.13%-2.74M | -6.64%-1.09M | 97.74%-6.06M | -4,941.41%-281.96M | -57.73%2.84M | -40.40%-15.35M | -116.26%-1.02M | -7,265.64%-268.43M |
Net common stock issuance | -97.05%8.25M | --0 | --1.47M | --6.78M | --0 | --279.75M | --0 | --0 | --0 | --279.75M |
Proceeds from stock option exercised by employees | --0 | --0 | --0 | ---- | ---- | ---2K | --0 | --0 | ---- | ---- |
Net other financing activities | 90.95%-604K | -1.47%-138K | -16.04%-123K | 59.47%-184K | 97.34%-159K | -584.82%-6.68M | 83.81%-136K | -146.51%-106K | -845.83%-454K | -13,493.18%-5.98M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 81.08%-1.68M | -83.98%433K | 90.96%-1.4M | 471.89%5.5M | -216.45%-6.22M | -283.40%-8.89M | -59.38%2.7M | -36.49%-15.46M | -124.86%-1.48M | 49.82%5.34M |
Net cash flow | ||||||||||
Beginning cash position | 76.78%30.84M | 28.73%15.65M | -36.71%26.03M | -52.11%10.24M | 76.78%30.84M | -18.89%17.45M | -43.42%12.16M | 83.51%41.12M | 7.19%21.37M | -18.89%17.45M |
Current changes in cash | -119.81%-2.67M | -33.18%12.42M | 64.36%-10.33M | -20.52%15.77M | -609.81%-20.52M | 445.46%13.46M | 556.19%18.59M | -3,404.84%-28.99M | 675.67%19.83M | 359.34%4.03M |
Effect of exchange rate changes | -359.38%-294K | -298.96%-191K | -304.55%-45K | 129.07%25K | 13.54%-83K | 61.90%-64K | 231.03%96K | 124.18%22K | 4.44%-86K | -500.00%-96K |
End cash Position | -9.60%27.88M | -9.60%27.88M | 28.73%15.65M | -36.71%26.03M | -52.11%10.24M | 76.78%30.84M | 76.78%30.84M | -43.42%12.16M | 83.51%41.12M | 7.19%21.37M |
Free cash flow | -107.50%-1.57M | -25.64%11.75M | 32.40%-9.25M | -51.54%10.26M | -502.40%-14.33M | 275.99%20.91M | 247.05%15.81M | -241.04%-13.69M | 705.00%21.16M | 67.58%-2.38M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |